← All trials
NCT05175014
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- May 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jan 3, 2022
- Last posted
- Jun 3, 2022
- Enrollment
- 32000
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EpicentreLead sponsor
- Kenya Medical Research InstituteCollaborator
- University of LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.